Yohann Bala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yohann Bala has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Delphine Farlay
INSERM, UMR 1033, University of Lyon, University Claude Bernard Lyon 1, F69622, Lyon, France
3 shared publications Georges Boivin
Université de Lyon
2 shared publications- Georges Boivin
INSERM, UMR 1033, Université de Lyon, 69372 Lyon, France
2 shared publications - Audrey Doublier
INSERM UMR 1033, F-69008 Lyon, France; Université de Lyon, F-69008 Lyon, France
1 shared publication Cécile Baron
Aix-Marseille University, CNRS, ISM UMR 7287, 13009 Marseille, France; APHM, Institute for Locomotion, Sainte-Marguerite Hospital, 13009 Marseille, France
1 shared publicationEmmanuelle Lefèvre
Aix-Marseille University, CNRS, ISM UMR 7287, 13009 Marseille, France; APHM, Institute for Locomotion, Sainte-Marguerite Hospital, 13009 Marseille, France
1 shared publication
Latest Publications
- 1 October 2016
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 63, 164-173
Pore network microarchitecture influences human cortical bone elasticity during growth and aging
- 1 October 2016
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 63, 164-173
Pore network microarchitecture influences human cortical bone elasticity during growth and aging
- 11 December 2012
- Published by Springer Nature in Osteoporosis International
- Vol. 24 (8) , 2153-2166
Bone mineralization: from tissue to crystal in normal and pathological contexts
Bone is a complex and structured material; its mechanical behavior results from an interaction between the properties of each level of its structural hierarchy. The degree of mineralization of bone (bone density measured at tissue level) and the characteristics of the mineral deposited (apatite crystals) are major determinants of bone strength. Bone remodeling activity acts as a regulator of the degree of mineralization and of the distribution of mineral at the tissue level, directly impacting bone mechanical properties. Recent findings have highlighted the need to understand the underlying process occurring at the nanostructure level that may be independent of bone remodeling itself. A more global comprehension of bone qualities will need further works designed to characterize what are the consequences on whole bone strength of changes at nano- or microstructure levels relative to each other.
- 11 December 2012
- Published by Springer Nature in Osteoporosis International
- Vol. 24 (8) , 2153-2166
Bone mineralization: from tissue to crystal in normal and pathological contexts
Bone is a complex and structured material; its mechanical behavior results from an interaction between the properties of each level of its structural hierarchy. The degree of mineralization of bone (bone density measured at tissue level) and the characteristics of the mineral deposited (apatite crystals) are major determinants of bone strength. Bone remodeling activity acts as a regulator of the degree of mineralization and of the distribution of mineral at the tissue level, directly impacting bone mechanical properties. Recent findings have highlighted the need to understand the underlying process occurring at the nanostructure level that may be independent of bone remodeling itself. A more global comprehension of bone qualities will need further works designed to characterize what are the consequences on whole bone strength of changes at nano- or microstructure levels relative to each other.
- 23 October 2012
- Published by Springer Nature in Calcified Tissue International
- Vol. 92 (1) , 6-14
Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization
Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34 months with an oral placebo (n = 36), 2.5 mg daily oral ibandronate (n = 40), or 20 mg intermittent oral ibandronate (n = 34). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34 months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34 months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r = 0.59–0.65, p < 0.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization.
- 23 October 2012
- Published by Springer Nature in Calcified Tissue International
- Vol. 92 (1) , 6-14
Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization
Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34 months with an oral placebo (n = 36), 2.5 mg daily oral ibandronate (n = 40), or 20 mg intermittent oral ibandronate (n = 34). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34 months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34 months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r = 0.59–0.65, p < 0.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization.
- 1 October 2011
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 165 (4) , 647-655
Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate
Objective: Given recent concern about long-term safety of bisphosphonate (BP) therapy, the effects of long-term alendronate (ALN) therapy on intrinsic bone properties were studied among postmenopausal osteoporotic (PMOP) women.Design and methods: Transiliac bone biopsies were obtained from 32 outpatient clinic PMOP women treated with oral ALN for 6.4±2.0 years. Variables reflecting bone mineralization were measured both at tissue level using quantitative microradiography and at crystal level by Fourier transform infrared microspectroscopy. Bone microhardness was investigated by Vickers indentation tests. Results were compared with those from 22 age-matched untreated PMOP women.Results: Long-term treatment with ALN was associated with a 84% (PP<0.05). Despite a more mature and more mineralized bone matrix, after treatment, cortical and trabecular microhardness and crystallinity were lower than that measured in untreated patients. None of the variables reflecting material properties were significantly correlated to the duration of the treatment.Conclusion: Increased degree of mineralization associated with lower crystallinity and microhardness in ALN long-term-treated PMOP women suggests that ALN could alter the quality of bone matrix. The study also suggested that after 3 years of treatment, the changes in material properties are not dependent on the duration of the treatment. Further studies are requested to assess the short-term (<3 years) effects of BPs on bone intrinsic properties.
- 1 October 2011
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 165 (4) , 647-655
Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate
Objective: Given recent concern about long-term safety of bisphosphonate (BP) therapy, the effects of long-term alendronate (ALN) therapy on intrinsic bone properties were studied among postmenopausal osteoporotic (PMOP) women.Design and methods: Transiliac bone biopsies were obtained from 32 outpatient clinic PMOP women treated with oral ALN for 6.4±2.0 years. Variables reflecting bone mineralization were measured both at tissue level using quantitative microradiography and at crystal level by Fourier transform infrared microspectroscopy. Bone microhardness was investigated by Vickers indentation tests. Results were compared with those from 22 age-matched untreated PMOP women.Results: Long-term treatment with ALN was associated with a 84% (PP<0.05). Despite a more mature and more mineralized bone matrix, after treatment, cortical and trabecular microhardness and crystallinity were lower than that measured in untreated patients. None of the variables reflecting material properties were significantly correlated to the duration of the treatment.Conclusion: Increased degree of mineralization associated with lower crystallinity and microhardness in ALN long-term-treated PMOP women suggests that ALN could alter the quality of bone matrix. The study also suggested that after 3 years of treatment, the changes in material properties are not dependent on the duration of the treatment. Further studies are requested to assess the short-term (<3 years) effects of BPs on bone intrinsic properties.